GT316

BIOLOGICAL2 trials

Sponsors

Grit Biotechnology

Conditions

AdultGT316Gynecological TumorsSolid Tumor

Early Phase 1

Autologous Tumor Infiltrating Lymphocyte Injection for the Treatment of Advanced Solid Tumors

TerminatedNCT06094426

Grit BiotechnologyAdult, GT316, Solid Tumor

Start: 2023-02-26End: 2025-12-30Updated: 2026-04-29

Unknown Phase

Clinical Study of Autologous Tumor Infiltrating Lymphocyte Injection (GT316) in the Treatment of Advanced Solid Tumors (Gynecological Tumors)

WithdrawnNCT06145802

Grit BiotechnologyGynecological Tumors, Solid Tumor

Start: 2023-03-09End: 2025-12-30Updated: 2026-04-29

Related Papers

Evaluating the safety and efficacy of CRISPR/AaCas12b <sup>Max</sup> -modified tumor infiltrating lymphocytes (GT300) as monotherapy in advanced solid tumors.

Journal of Clinical Oncology2025-05-281 citations

A first-in-human study of CRISPR/Cas9-engineered tumor infiltrating lymphocytes (TILs) product GT316 as monotherapy in advanced solid tumors.

Journal of Clinical Oncology2024-06-012 citations